Raymond B. Mailhot, MD, MPH
Assistant Professor, University of Florida Department of Radiation Oncology,
UF Health Proton Therapy Institute
Dr. Mailhot has disclosed that he has no relevant financial relationships. No one else in a position to control content has any financial relationships to disclose. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. All relevant financial relationships have been mitigated.
Release Date: October 18, 2021
Expiration Date: October 17, 2022
Target Audience: This course is intended for an audience of specialty physicians, primary care physicians, physician assistants, nurses, as well as others who treat patients with Hodgkin lymphoma.
As a result of participation in this activity, participants should be able to:
- Discuss best practices of the use of radiation therapy for Hodgkin lymphoma based on current research.
- Define proton therapy and describe how proton therapy is different from conventional radiation therapy.
- Identify and determine the theoretical advantages to the use of proton therapy in the treatment of Hodgkin lymphoma.
Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.
Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Resource(s) for further study:
1) Hoppe BS, Mailhot Vega RB, Mendenhall NP, et al. Irradiating Residual Disease to 30 Gy with Proton Therapy in Pediatric Mediastinal Hodgkin Lymphoma. Int J Part Ther. 2020;6(4):11-16. doi:10.14338/IJPT-19-00077.1
2) Raymond B. Mailhot Vega & Bradford S. Hoppe (2020) A positive approach: advances in proton therapy for the treatment of mediastinal lymphoma, Expert Review of Hematology, 13:3, 197-200, DOI: 10.1080/17474086.2020.1713745
3) Hoppe BS, Bates JE, Mendenhall NP, et al. The Meaningless Meaning of Mean Heart Dose in Mediastinal Lymphoma in the Modern Radiation Therapy Era. Pract Radiat Oncol. 2020;10(3):e147-e154. doi:10.1016/j.prro.2019.09.015
If you have any questions please feel free to contact Christina Mershell at (904) 831-4034 or email@example.com.